Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

July 12, 2017

Study Completion Date

December 27, 2017

Conditions
Influenza
Interventions
BIOLOGICAL

AdimFlu-S (QIS)

This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.

Sponsors
All Listed Sponsors
lead

Adimmune Corporation

INDUSTRY

NCT04101435 - Immunogenicity and Safety Evaluation of QIS in Healthy Subjects | Biotech Hunter | Biotech Hunter